119 related articles for article (PubMed ID: 31589435)
1. Enzyme-Instructed Activation of Pro-protein Therapeutics In Vivo.
Chang J; Cai W; Liang C; Tang Q; Chen X; Jiang Y; Mao L; Wang M
J Am Chem Soc; 2019 Nov; 141(45):18136-18141. PubMed ID: 31589435
[TBL] [Abstract][Full Text] [Related]
2. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
Colucci MA; Moody CJ; Couch GD
Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
Qu Y; Zhang C; Ma X; Gao Y; Liu J; Wu L
Bioorg Med Chem; 2020 Dec; 28(24):115821. PubMed ID: 33091789
[TBL] [Abstract][Full Text] [Related]
4. Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.
Mendoza MF; Hollabaugh NM; Hettiarachchi SU; McCarley RL
Biochemistry; 2012 Oct; 51(40):8014-26. PubMed ID: 22989153
[TBL] [Abstract][Full Text] [Related]
5. Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment.
Yang X; Duan J; Wu L
Future Med Chem; 2022 Mar; 14(5):363-383. PubMed ID: 35102756
[TBL] [Abstract][Full Text] [Related]
6. 3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro.
Jaffar M; Phillips RM; Williams KJ; Mrema I; Cole C; Wind NS; Ward TH; Stratford IJ; Patterson AV
Biochem Pharmacol; 2003 Oct; 66(7):1199-206. PubMed ID: 14505799
[TBL] [Abstract][Full Text] [Related]
7. A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy.
Liu P; Xu J; Yan D; Zhang P; Zeng F; Li B; Wu S
Chem Commun (Camb); 2015 Jun; 51(46):9567-70. PubMed ID: 25971544
[TBL] [Abstract][Full Text] [Related]
8. NQO1-selective activated prodrugs of combretastatin A-4: Synthesis and biological evaluation.
Zhang C; Qu Y; Ma X; Li M; Li S; Li Y; Wu L
Bioorg Chem; 2020 Oct; 103():104200. PubMed ID: 32890998
[TBL] [Abstract][Full Text] [Related]
9. Betulin-1,4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme.
Kadela-Tomanek M; Bębenek E; Chrobak E; Marciniec K; Latocha M; Kuśmierz D; Jastrzębska M; Boryczka S
Eur J Med Chem; 2019 Sep; 177():302-315. PubMed ID: 31158746
[TBL] [Abstract][Full Text] [Related]
10. Intracellular delivery of therapeutic proteins through N-terminal site-specific modification.
Liew SS; Zhang C; Zhang J; Sun H; Li L; Yao SQ
Chem Commun (Camb); 2020 Sep; 56(77):11473-11476. PubMed ID: 32856656
[TBL] [Abstract][Full Text] [Related]
11. Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).
Fryatt T; Pettersson HI; Gardipee WT; Bray KC; Green SJ; Slawin AM; Beall HD; Moody CJ
Bioorg Med Chem; 2004 Apr; 12(7):1667-87. PubMed ID: 15028260
[TBL] [Abstract][Full Text] [Related]
12. Developing chemically modified redox-responsive proteins as smart therapeutics.
Tang Q; Wang J; Jiang Y; Zhang M; Chang J; Xu Q; Mao L; Wang M
Chem Commun (Camb); 2019 Apr; 55(35):5163-5166. PubMed ID: 30984934
[TBL] [Abstract][Full Text] [Related]
13. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
[TBL] [Abstract][Full Text] [Related]
14. Intracellular Enzyme-Responsive Profluorophore and Prodrug Nanoparticles for Tumor-Specific Imaging and Precise Chemotherapy.
Pei Q; Lu S; Zhou J; Jiang B; Li C; Xie Z; Jing X
ACS Appl Mater Interfaces; 2021 Dec; 13(50):59708-59719. PubMed ID: 34879654
[TBL] [Abstract][Full Text] [Related]
15. Efficient NQO1 substrates are potent and selective anticancer agents.
Parkinson EI; Bair JS; Cismesia M; Hergenrother PJ
ACS Chem Biol; 2013 Oct; 8(10):2173-83. PubMed ID: 23937670
[TBL] [Abstract][Full Text] [Related]
16. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
17. Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1.
Beall HD; Hudnott AR; Winski S; Siegel D; Swann E; Ross D; Moody CJ
Bioorg Med Chem Lett; 1998 Mar; 8(5):545-8. PubMed ID: 9871615
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel isothiazoloquinoline quinone analogues.
Chen L; Xie YZ; Luo ZY; Liu LJ; Zou ZZ; Liu HD; Kong FR; Hao Y; Gao JL; Wang LL; Ma DY; Liu SY
Bioorg Med Chem Lett; 2020 Aug; 30(16):127286. PubMed ID: 32631508
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
Xu S; Yao H; Pei L; Hu M; Li D; Qiu Y; Wang G; Wu L; Yao H; Zhu Z; Xu J
Eur J Med Chem; 2017 May; 132():310-321. PubMed ID: 28395199
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
Bailey SM; Suggett N; Walton MI; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
